KCM
KRYS icon

Kynam Capital Management’s Krystal Biotech KRYS Stock Holding History

Kynam Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,393
Closed -$1.22M – 35
2022
Q1 		$1.22M Sell
18,393
-16,423
-47% -$1.03M 0.4% 27
2021
Q4 		$2.44M Buy
+34,816
New +$2.03M 1.3% 23

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Kynam Capital Management's KRYS Position: Q2 2022 in Review

Kynam Capital Management sold out of Krystal Biotech (KRYS) in Q2 2022, closing a stake of 18,393 shares — an estimated $1.22M sold.

Kynam Capital Management first reported a position in KRYS in Q4 2021 and held it in 2 quarters. The position peaked at $2.44M in Q4 2021. 137 funds tracked by Wall St. Rank hold KRYS as of Q2 2022.

  • Kynam Capital Management reported no remaining Krystal Biotech position as of Q2 2022 after selling out during the quarter.
  • Kynam Capital Management sold 18,393 Krystal Biotech shares in Q2 2022, an estimated $1.22M.
  • Kynam Capital Management first reported a position in Krystal Biotech in Q4 2021 and held it in 2 quarters.
  • Kynam Capital Management's Krystal Biotech position peaked at $2.44M in Q4 2021.
  • 137 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2022.

Based on Kynam Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.